Companies Dominating the Pulmonary Drug Delivery Systems Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Lupin Limited
- Briggs Healthcare, Inc.
- Boehringer Ingelheim International GmbH
- Koninklijke Philips N.V.
- Merck & Co., Inc.
- 3M Company
- AstraZeneca PLC
- GSK plc
- GF Health Products, Inc.
Browse Key Market Insights with Data Illustration:
In the News
-
Novartis AG reported that a new treatment option for Japanese patients was approved by the Ministry of Health, Labour, and Welfare (MHLW). NSCLC with METex14 mutations can be treated with TabrectaTM (capmatinib, formerly INC280), an oral MET inhibitor. Tabrecta became the first-line approved treatment type for patients living with lung cancer advanced non-small cell lung cancer.
-
Lupin Limited launched Adhero, a smart inhaler tracking device designed to support the treatment of COPD patients and respiratory diseases. Adhero also provide therapy and assistance to the people living with chronic respiratory diseases. Additionally, Adhero is getting fame owing to the fact that inhalers are most convenient treatment methods for chronic respiratory diseases.
